Home/Pipeline/Prenatal Down Syndrome Testing

Prenatal Down Syndrome Testing

Trisomy 21 (Down syndrome)

CommercialActive

Key Facts

Indication
Trisomy 21 (Down syndrome)
Phase
Commercial
Status
Active
Company

About Ravgen

Ravgen is a private, commercial-stage diagnostics company with a proprietary platform for enriching fetal DNA from maternal blood samples, enabling non-invasive prenatal testing (NIPT). The company's primary offerings include tests for Down syndrome, other chromosomal abnormalities, single-gene disorders, and prenatal paternity, all aimed at providing safer alternatives to invasive procedures. Led by founder and CEO Dr. Ravinder Dhallan, Ravgen has published foundational research in top-tier journals and appears to generate revenue through its testing services and potential partnerships. Its strategic position leverages a growing global NIPT market but faces significant competition from larger, established players.

View full company profile

Therapeutic Areas